

CRCMonitorTM

Test Report



CellMaxLife

Order Information

Requisition Number	
Patient Name	
ID	
Date of Birth	
Gender	
Patient Phone Number	
Patient E-mail	
Name of Lab	
Lab Phone Number	
Name of Physician	
Date of Collection	
Date of Report	

Patient Test Result

Current CTC Count	
Current CTC Trend	
Recommendation	

Comments

Electronic Signatures

Leon Chen 陳律吾
Manager, Clinical Laboratory

Leon Chen.

Date

Manana Kvezereli-Javey, MD, PhD
Medical Director, CellMax Inc

M. Javey

Date

Patient History


Type of cancer Colon Cancer

Stage of diagnosis _____ Date of diagnosis _____

Notes

Testing History

Test Date	CTC counts



About CRC Monitor™

CellMax CRC Monitor™ is a proprietary in-vitro clinical assay. Using CellMax Life's patented CMx Platform, it detects a biological tumor marker in the blood, called a Circulating Tumor Cell (CTC), to predict the recurrence / metastasis of colorectal cancer.





Who Should Consider CRC Monitor™

CellMax CRC Monitor™ can be used by CRC patients who underwent surgical or conservative treatment to monitor the disease for recurrence or metastasis. Cancer is an evolving disease - therefore continuous monitoring and early detection is the key to a patient's survival rate! More than 50% of CRC cases recur within the first three years following surgical resection. Hence, it is recommended that patients take the test every 3 months for early detection of recurrence.

Clinical Utility of CRC Monitor™

CRC Monitor Result Interpretation:

A "Low" CTC trend translates into a low probability of CRC recurrence, while a "High" CTC trend is an alert to trigger further medical workup for recurrence. A small percentage of patients fall within the "Indeterminate" CTC trend category, interpretation of which is equivocal, hence the patient is advised to continue testing every 3 months.



References

1. Hao-Wei Teng, et al. "A new classification scheme for recurrent or metastatic colon cancer after liver metastasectomy" . JCMS 74, p.493, 2011
2. Stewart BW, Wild CP, (Ed.). World Cancer Report 2014. International Agency for Research on Cancer, Lyon,France, 2014.
3. Chen et al, Int J Colorectal Dis. 2010 May;25(5):567-71.
4. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Wolff BG, Surg Gynecol Obstet. 1992 Jan; 174(1):27-32.
5. Millner et al. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013 Summer;43(3):295-304.
6. Nesteruk, et al. "Evaluation of Prognostic Significance of Circulating Tumor Cells Detection in Rectal Cancer Patients Treated with Preoperative Radiotherapy: Prospectively Collected Material Data." BioMed Research International, vol. 2014, Article ID 712827, 6 pages, 2014.
7. Shen et al, "Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker," Exp. Ther. Med; Volume 2 Issue 3; May 2011
8. Public domain image, National Cancer Institute, USA
9. Rahbari et al. "Meta-analysis Shows That Detection of Circulating Tumor Cells Indicates Poor Prognosis in Patients With Colorectal Cancer." Gastroenterology 2010;138:1714–1726
10. Marchetti et al. "Circulating Tumor Cells Count Predicts Survival in Colorectal Cancer Patients." J Gastrointest Liver Dis, September 2014 Vol. 23 No 3: 279-284 2014
11. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008 Jul;26 (19):3212-3221
12. Klein, et al. "Systemic spread is an early step in breast cancer," Cancer Cell. 2008 Jan;13(1):5868
13. Yang et al. Epithelial–mesenchymal plasticity in carcinoma metastasis. Genes & Dev. 2013. 27: 2192-2206
14. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791
15. deBono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in the metastatic castration-resistant prostate cancer. Clin Cancer Res 2008 October 1;14(19):6302-6309
16. Budd TG, Cristofanilli M, Ellis MJ, et al: Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer. Clin Cancer Res 2006 12:6403-6409

Disclaimer

This test was developed and its performance characteristics determined by CellMax Life. Clinical decisions regarding care and treatment of patients should not be solely based on this test. Not all disease will be accurately detected. How this information is used to guide patient care is the responsibility of the physician.

The CellMax Life test is designed to assist health care practitioners in providing additional clinical information. The information therein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. Medical knowledge develops rapidly and new evidence may emerge between the time information is developed to when it is published or read.

CellMax Life provides this information on an "as is" basis, and makes no warranty, express or implied, regarding the information. CellMax specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. CellMax Life assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

The information herein is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating physician, as the information does not account for individual variation among patients.

Simple Blood Test. Real Time Protection.



CellMax Life

合度精密生物科技有限公司 / 合度醫事檢驗所

🏠: 台北市115南港區園區街3號18樓之一 | 18F-1, No. 3 Park Street, Nangang, Taipei City, Taiwan

☎: 0800-555-885

🌐: www.cellmaxlife.com

